Patents by Inventor Wenqing Yao

Wenqing Yao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20200172545
    Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. Also provided are methods of using the compounds of Formula (I) for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: October 3, 2019
    Publication date: June 4, 2020
    Inventors: Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20200172533
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 4, 2020
    Inventors: Liangxing Wu, Fenglei Zhang, Song Mei, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 10669271
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: June 2, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Jingwei Li, Wenqing Yao
  • THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
    Publication number: 20200155527
    Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Application
    Filed: November 15, 2019
    Publication date: May 21, 2020
    Inventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Jun Pan, Anlai Wang, Ke Zhang, Wenqing Yao, Fenglei Zhang, Jincong Zhuo
  • Heterocyclylamines as PI3K inhibitors
    Patent number: 10646492
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: May 12, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Song Mei, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks
  • Imidazopyridines and imidazopyrazines as LSD1 inhibitors
    Patent number: 10640503
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 5, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 10632126
    Abstract: The present disclosure relates to bicyclic heterocycles of Formula (I?), and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: April 28, 2020
    Assignee: Incyte Corporation
    Inventors: Alexander Sokolsky, Liangxing Wu, Wenqing Yao
  • DIHYDROPYRIDO[2,3-D]PYRIMIDINONE COMPOUNDS AS CDK2 INHIBITORS
    Publication number: 20200115378
    Abstract: The present application provides dihydropyrido[2,3-d]pyrimidone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: October 10, 2019
    Publication date: April 16, 2020
    Inventors: Alexander Sokolsky, Liangxing Wu, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 10618916
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: April 14, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Kaijiong Xiao, Wenqing Yao
  • PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20200095250
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and/or FGFR activity, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity and/or FGFR activity, such as cancer.
    Type: Application
    Filed: September 24, 2019
    Publication date: March 26, 2020
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20200095244
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: September 10, 2019
    Publication date: March 26, 2020
    Inventors: Yaping Sun, Liang Lu, Wenqing Yao, Jincong Zhuo, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Chunhong He, Fenglei Zhang
  • PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20200087301
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: August 20, 2019
    Publication date: March 19, 2020
    Inventors: Oleg Vechorkin, Jun Pan, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20200079783
    Abstract: The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAKs) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: November 13, 2019
    Publication date: March 12, 2020
    Inventors: Wenqing Yao, David M. Burns, Jincong Zhuo
  • BENZOTHIAZOLE COMPOUNDS AND USES THEREOF
    Publication number: 20200048241
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: August 7, 2019
    Publication date: February 13, 2020
    Inventors: Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
  • Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
    Patent number: 10556908
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 11, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS
    Publication number: 20200039994
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: July 31, 2019
    Publication date: February 6, 2020
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
  • TRICYCLIC HETERARYL COMPOUNDS AS STING ACTIVATORS
    Publication number: 20200040009
    Abstract: The present application provides tricyclic heteroaryl compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: July 31, 2019
    Publication date: February 6, 2020
    Inventors: Liangxing Wu, Yingda Ye, Wenqing Yao
  • FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
    Publication number: 20200031835
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 30, 2020
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Wenyu Zhu
  • TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS
    Publication number: 20200024277
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: October 3, 2019
    Publication date: January 23, 2020
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
    Patent number: 10513522
    Abstract: The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAKs) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: December 24, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Wenqing Yao, David M. Burns, Jincong Zhuo